论文部分内容阅读
目的探讨核苷酸还原酶1(RRM1)蛋白表达与吉西他滨治疗晚期非小细胞肺癌疗效的关系。方法回顾性分析44例接受含吉西他滨方案一线化疗的晚期非小细胞肺癌的RRM1表达,免疫组化检测肿瘤标本的RRM1表达,并对化疗疗效进行分析。结果 44例患者中,RRM1阳性40.9%,RRM1阴性59.1%。总客观有效率38.6%,疾病控制率75.0%;其中RRM1阴性患者的客观有效率与RRM1阳性患者无明显差异(46.2%和27.8%,P=0.218);但RRM1阴性患者的疾病控制率明显高于RRM1阳性患者(88.5%和55.6%,P=0.013)。44例患者的中位无疾病进展时间为6.8个月,中位生存时间为15.4个月;其中RRM1阴性患者的中位无疾病进展时间较RRM1阳性患者长(7.2个月和5.5个月,P=0.01);但中位生存时间无明显差异(18.8个月和15.3个月,P=0.127)。结论 RRM1表达水平可能与吉西他滨的疗效相关,可能是预测吉西他滨治疗晚期非小细胞肺癌疗效的生物标志物之一。
Objective To investigate the relationship between the expression of nucleotide reductase 1 (RRM1) and the efficacy of gemcitabine in the treatment of advanced non-small cell lung cancer. Methods The expression of RRM1 in 44 patients with advanced non-small cell lung cancer receiving first-line chemotherapy with gemcitabine was retrospectively analyzed. The expression of RRM1 in tumor samples was detected by immunohistochemistry and the effect of chemotherapy was analyzed. Results Of 44 patients, RRM1 was 40.9% positive and RRM1 negative was 59.1%. The total objective effective rate was 38.6% and disease control rate was 75.0%. The objective effective rate of RRM1-negative patients was not significantly different from that of RRM1-positive patients (46.2% vs 27.8%, P = 0.218); however, RRM1-negative patients had significantly higher disease control rate In RRM1-positive patients (88.5% and 55.6%, P = 0.013). The median progression-free time was 6.8 months and the median survival time was 15.4 months in 44 patients. The median progression-free time was longer in RRM1-negative patients than in RRM1-positive patients (7.2 months and 5.5 months, P = 0.01). However, there was no significant difference in median survival (18.8 months vs 15.3 months, P = 0.127). Conclusion The expression of RRM1 may be related to the efficacy of gemcitabine, which may be one of the biomarkers for predicting the efficacy of gemcitabine in the treatment of advanced non-small cell lung cancer.